99.26
price down icon0.61%   -0.61
 
loading
Kodiak Sciences Inc stock is traded at $99.26, with a volume of 1.33M. It is down -0.61% in the last 24 hours and up +201.79% over the past month. Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
See More
Previous Close:
$99.87
Open:
$100.08
24h Volume:
1.33M
Relative Volume:
0.47
Market Cap:
$6.24B
Revenue:
Net Income/Loss:
$-230.66M
P/E Ratio:
-23.78
EPS:
-4.1742
Net Cash Flow:
$-148.12M
1W Performance:
+7.49%
1M Performance:
+201.79%
6M Performance:
+136.62%
1Y Performance:
+755.69%
1-Day Range:
Value
$0.00
$0.00
1-Week Range:
Value
$89.54
$103.27
52-Week Range:
Value
$10.94
$104.00

Kodiak Sciences Inc Stock (KOD) Company Profile

Name
Name
Kodiak Sciences Inc
Name
Phone
650-281-0850
Name
Address
1250 PAGE MILL RD, PALO ALTO, CA
Name
Employee
124
Name
Twitter
@kodiaksciences
Name
Next Earnings Date
2026-11-12
Name
Latest SEC Filings
Name
KOD's Discussions on Twitter

Compare KOD vs VRTX, MRNA, REGN, ARGX, RVMD

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
KOD icon
KOD
Kodiak Sciences Inc
99.26 6.24B 0 -230.66M -148.12M -4.1742
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
507.00 128.50B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
213.74 85.33B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
762.81 78.54B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
812.30 51.08B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
193.95 41.57B 742.00K -1.37B -1.07B -7.0731

Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-24-26 Resumed Goldman Neutral
May-11-26 Upgrade Chardan Capital Markets Neutral → Buy
Nov-11-25 Upgrade H.C. Wainwright Neutral → Buy
Oct-24-25 Upgrade JP Morgan Neutral → Overweight
Sep-25-25 Upgrade Barclays Underweight → Equal Weight
Sep-22-25 Initiated Jefferies Buy
Aug-14-25 Upgrade JP Morgan Underweight → Neutral
Dec-09-24 Upgrade Jefferies Hold → Buy
Sep-05-24 Initiated H.C. Wainwright Neutral
Dec-11-23 Resumed Goldman Sell
Nov-17-23 Upgrade CapitalOne Equal Weight → Overweight
Jul-27-23 Downgrade UBS Buy → Neutral
Jul-25-23 Downgrade Chardan Capital Markets Buy → Neutral
Jul-25-23 Downgrade JP Morgan Neutral → Underweight
Jul-24-23 Downgrade CapitalOne Overweight → Equal Weight
Jul-24-23 Downgrade Jefferies Buy → Hold
Nov-15-22 Initiated CapitalOne Overweight
Aug-02-22 Downgrade Citigroup Neutral → Sell
Feb-24-22 Downgrade JP Morgan Overweight → Neutral
Feb-11-22 Initiated Goldman Buy
Feb-02-22 Upgrade JP Morgan Neutral → Overweight
May-11-21 Upgrade ROTH Capital Neutral → Buy
Mar-12-21 Initiated Evercore ISI Outperform
Mar-01-21 Downgrade Barclays Equal Weight → Underweight
Feb-17-21 Downgrade ROTH Capital Buy → Neutral
Jan-25-21 Downgrade BMO Capital Markets Outperform → Market Perform
Dec-17-20 Initiated Berenberg Buy
Dec-16-20 Initiated UBS Buy
Dec-11-20 Initiated Citigroup Neutral
Nov-30-20 Downgrade JP Morgan Overweight → Neutral
Nov-16-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-13-20 Downgrade Goldman Buy → Neutral
Mar-31-20 Initiated BMO Capital Markets Outperform
Mar-03-20 Initiated Goldman Buy
Feb-18-20 Downgrade Barclays Overweight → Equal Weight
Feb-06-20 Initiated SunTrust Buy
Jan-08-20 Initiated ROTH Capital Buy
Jan-03-20 Initiated Jefferies Buy
Dec-24-19 Initiated JP Morgan Overweight
Oct-15-19 Reiterated Chardan Capital Markets Buy
Feb-20-19 Initiated Chardan Capital Markets Buy
Oct-29-18 Initiated Barclays Overweight
Oct-29-18 Initiated BofA/Merrill Buy
Oct-29-18 Initiated Morgan Stanley Overweight
View All

Kodiak Sciences Inc Stock (KOD) Latest News

pulisher
Oct 09, 2026

Kodiak Sciences Inc. (KOD) stock price, news, quote and history - Yahoo Finance Singapore

Oct 09, 2026
pulisher
Oct 01, 2026

Kodiak Sciences More Than Doubles on Eye Disease Trial Results - Barchart.com

Oct 01, 2026
pulisher
Oct 01, 2026

Form 13D/A Kodiak Sciences Inc. For: 1 October By Investing.com - Investing.com South Africa

Oct 01, 2026
pulisher
Oct 01, 2026

Form 13D/A Kodiak Sciences Inc. For: 1 October By Investing.com - Investing.com Nigeria

Oct 01, 2026
pulisher
Oct 01, 2026

Form 13D/A Kodiak Sciences Inc. For: 1 October By Investing.com - Investing.com Canada

Oct 01, 2026
pulisher
Sep 30, 2026

Kodiak Sciences(KOD.US) 10% Shareholder Buys US$156.99 Million in Common Stock - Moomoo

Sep 30, 2026
pulisher
Sep 30, 2026

A stock acquisition changes beneficial ownership by more than 1% at Kodiak Sciences (KOD). - Stock Titan

Sep 30, 2026
pulisher
Sep 30, 2026

Baker Bros. Advisors Reports Multiple Open-Market Buys of Kodiak Sciences Stock - Kalkine Media

Sep 30, 2026
pulisher
Sep 30, 2026

In 30 transactions, Baker funds bought shares of Kodiak Sciences (KOD). - Stock Titan

Sep 30, 2026
pulisher
Sep 30, 2026

Funds buy Kodiak Sciences (KOD) shares at average prices of about $79–$86. - Stock Titan

Sep 30, 2026
pulisher
Sep 30, 2026

Form 4 Kodiak Sciences Inc For: 29 September By Investing.com - Investing.com Canada

Sep 30, 2026
pulisher
Sep 29, 2026

Form 4 Kodiak Sciences Inc For: 29 September By Investing.com - Investing.com South Africa

Sep 29, 2026
pulisher
Sep 29, 2026

Form 4 Kodiak Sciences Inc For: 29 September By Investing.com - Investing.com Nigeria

Sep 29, 2026
pulisher
Sep 29, 2026

Options at $2.49 a share are among those Kodiak Sciences (KOD) CEO exercised. - Stock Titan

Sep 29, 2026
pulisher
Sep 29, 2026

Diluted net income available to common stockholders of Kodiak Sciences, Inc. – HAN:K27 - TradingView

Sep 29, 2026
pulisher
Sep 29, 2026

KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears - Zacks Investment Research

Sep 29, 2026
pulisher
Sep 28, 2026

Kodiak Sciences Inc (NASDAQ: KOD) Share Price, KOD Stock News, KOD Share Price & Updates - Kalkine

Sep 28, 2026
pulisher
Sep 28, 2026

Form 8K Kodiak Sciences Inc For: 28 September By Investing.com - Investing.com Canada

Sep 28, 2026
pulisher
Sep 28, 2026

Form 8K Kodiak Sciences Inc For: 28 September By Investing.com - Investing.com India

Sep 28, 2026
pulisher
Sep 28, 2026

Both treatments met a year-one vision goal in Kodiak Sciences (KOD)'s eye disease trial. - Stock Titan

Sep 28, 2026
pulisher
Sep 28, 2026

Why Is Kodiak Sciences (NASDAQ:KOD) Suddenly a Must-Watch Healthcare Stocks Name? - Kalkine Media

Sep 28, 2026
pulisher
Sep 28, 2026

Kodiak Sciences (Nasdaq:KOD)Stock Analysis - Simply Wall Street

Sep 28, 2026
pulisher
Sep 28, 2026

Kodiak Stock Soars (Again) As Data Shows Long-Lasting Eye Meds Are The 'Real Deal' (KOD) - Seeking Alpha

Sep 28, 2026
pulisher
Sep 25, 2026

Kodiak Sciences to report phase 3 trial results Monday By Investing.com - Investing.com South Africa

Sep 25, 2026
pulisher
Sep 24, 2026

What DAYBREAK Trial Results Could Mean For Kodiak Sciences Stock - simplywall.st

Sep 24, 2026
pulisher
Sep 24, 2026

Goldman Sachs initiates Kodiak Sciences stock coverage with neutral rating - Investing.com

Sep 24, 2026
pulisher
Sep 23, 2026

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research

Sep 23, 2026
pulisher
Sep 21, 2026

Kodiak Sciences (KOD) Pulls Back After A Strong Year, Is The Valuation Still Too Rich? - simplywall.st

Sep 21, 2026
pulisher
Sep 17, 2026

H.C. Wainwright reiterates Kodiak Sciences stock rating on trial outlook By Investing.com - Investing.com South Africa

Sep 17, 2026
pulisher
Sep 17, 2026

H.C. Wainwright reiterates Kodiak Sciences stock rating on trial outlook - Investing.com India

Sep 17, 2026
pulisher
Sep 16, 2026

After $435,870 sale, Gilead (NASDAQ: GILD) CFO still holds 164K shares - Stock Titan

Sep 16, 2026
pulisher
Sep 13, 2026

3 Small-Cap Biotechs With Binary Catalysts on the Calendar - marketbeat.com

Sep 13, 2026
pulisher
Sep 03, 2026

Kodiak Sciences (KOD) Races Toward Three Make-Or-Break Trial Verdicts - Yahoo Finance

Sep 03, 2026
pulisher
Sep 01, 2026

Kodiak Sciences (KOD): Three Phase 3 Readouts In SightWill The Data See It Through? - RTTNews

Sep 01, 2026
pulisher
Sep 01, 2026

Former Sight Sciences (NASDAQ: SGHT) officer lines up more share sales after a string of summer trades - Stock Titan

Sep 01, 2026
pulisher
Aug 27, 2026

Kodiak Sciences Inc (KOD) Peer Comparison – Compare with Others - valueresearchonline.com

Aug 27, 2026
pulisher
Aug 26, 2026

What Kodiak Sciences (KOD)'s Widening Net Losses and Lower H1 Loss Per Share Mean For Shareholders - simplywall.st

Aug 26, 2026
pulisher
Aug 24, 2026

BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants - Yahoo Finance

Aug 24, 2026
pulisher
Aug 21, 2026

Kodiak Sciences (NASDAQ:KOD) Stock Price Down 4.1%Time to Sell? - MarketBeat

Aug 21, 2026
pulisher
Aug 20, 2026

Kodiak Sciences enrolls first patients in phase 3 DME trial By Investing.com - Investing.com Nigeria

Aug 20, 2026
pulisher
Aug 19, 2026

HC Wainwright Lowers Earnings Estimates for Kodiak Sciences - MarketBeat

Aug 19, 2026
pulisher
Aug 18, 2026

GSA Capital Partners LLP Takes $1.07 Million Position in Kodiak Sciences Inc. $KOD - MarketBeat

Aug 18, 2026
pulisher
Aug 17, 2026

KOD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $58 - GuruFocus

Aug 17, 2026
pulisher
Aug 17, 2026

H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com Nigeria

Aug 17, 2026
pulisher
Aug 17, 2026

HC Wainwright Reaffirms "Buy" Rating for Kodiak Sciences (NASDAQ:KOD) - MarketBeat

Aug 17, 2026
pulisher
Aug 17, 2026

H.C. Wainwright reiterates Kodiak Sciences stock rating at buy - Investing.com

Aug 17, 2026
pulisher
Aug 17, 2026

H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com India

Aug 17, 2026
pulisher
Aug 17, 2026

H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com UK

Aug 17, 2026
pulisher
Aug 17, 2026

H.C. Wainwright reiterates Kodiak Sciences stock rating at buy - Investing.com

Aug 17, 2026
pulisher
Aug 17, 2026

H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $58 - Moomoo

Aug 17, 2026

Kodiak Sciences Inc Stock (KOD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Kodiak Sciences Inc Stock (KOD) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
BAKER BROS. ADVISORS LP
Director
Sep 29 '26
Buy
85.05
33,726
2,868,255
20,191,214
BAKER BROS. ADVISORS LP
Director
Sep 28 '26
Buy
83.58
418,323
34,963,077
19,515,907
BAKER BROS. ADVISORS LP
Director
Sep 28 '26
Buy
72.57
807,840
58,625,708
19,121,134
PERLROTH VICTOR
Chairman and CEO
Sep 25 '26
Option Exercise
4.20
1,280,524
5,381,943
3,676,062
BORGESON JOHN A.
Chief Financial Officer
Jun 04 '26
Sale
34.10
30,000
1,023,009
211,930
JOHN BORGESON
Officer
Jun 04 '26
Proposed Sale
33.87
30,000
1,016,100
0
BORGESON JOHN A.
Chief Financial Officer
Jun 04 '26
Option Exercise
1.04
30,000
31,200
241,930
BORGESON JOHN A.
Chief Financial Officer
Apr 15 '26
Option Exercise
1.04
28,614
29,759
211,930
JOHN BORGESON
Officer
Apr 02 '26
Proposed Sale
42.81
30,000
1,284,300
0
BORGESON JOHN A.
Chief Financial Officer
Apr 02 '26
Sale
39.92
30,000
1,197,488
183,316
$311.13
price up icon 3.09%
$89.82
price down icon 1.06%
$158.59
price up icon 2.65%
$29.48
price down icon 3.25%
$14.56
price down icon 0.41%
$63.13
price down icon 1.08%
Cap:     |  Volume (24h):